ASH 2022 | Insights into new BiTE developments in multiple myeloma
Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, comments on the merits of novel bispecific T-cell engager (BiTE) drugs designed to treat myeloma, commenting on the recent approval of teclistamab as well as promising drugs guided by epitopes other than the B-cell maturation antigen (BCMA). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Ionis/Akcea: Other: personal fees; Prothena: Other: personal fees; Sanofi: Other: personal fees; Janssen: Other: personal fees; Aptitude Healthgrants: Other: personal fees; Ashfield: Other: personal fees; Juno: Other: personal fees; Physicians Education Resource: Other: personal fees; Abbvie: Membership on an entity’s Board of Directors or advisory committees, Other: personal fees from Data Safety Monitoring Board; Johnson & Johnson: Other: personal fees; Celgene: Other: personal fees; Research to Practice: Other: personal fees; Sorrento: Other: personal fees; i3Health: Other: Development of educational materials for i3Health.
